# **Pregnancy Outcomes in Patients Treated** With Ocrelizumab



### C Oreja-Guevara,<sup>1</sup> S Wray,<sup>2</sup> R Buffels,<sup>3</sup> D Zecevic,<sup>3</sup> S Vukusic<sup>4</sup>

<sup>1</sup>Hospital Clinico San Carlos, Madrid, Spain; <sup>2</sup>Sibyl Wray MD Neurology PC, Knoxville, TN, USA; <sup>3</sup>F. Hoffmann-La Roche Ltd, Basel, Switzerland; \*Service de Neurologie et Sclérose en Plaques, Fondation EDMUS pour la Sclérose en Plaques, Hôpital Neurologique Pierre Wertheimer, Lyon, France

RESULTS

**Overall Patient Expose** 

es, each res eron; MS, m

Pregnancy ongoing Live birth Healthy baby Preterm birth®

ive termina

Ectopic pregnancy Still birth

Unknown outcome<sup>e</sup>

31 March 2019

#### **INTRODUCTION AND PURPOSE**

- Ocrelizumab (OCR), a humanised monoclonal antibody that selectively targets CD20\* B cells, is approved for the treatment of relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS)<sup>12</sup>
- A total of 4,611 patients have received OCR in clinical trials (as of 7 January 2019)
- Approximately 93,572 patients have received OCR in the post-marketing setting (as of 31 March 2019)
- Estimated patient exposures from clinical trials and the post-marketing setting are 14,329° and 80,276° patient years, respectively
   A significant proportion of patients eligible for treatment with OCR will be women of
- reproductive age
- Mean age of RMS onset is approximately 30 years<sup>3</sup>
   Female-to-male ratio of patients with RMS is approximately 3:1<sup>3</sup>
- Nonclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity and embryo-foetal development'

#### For a summary of pre-clinical data, please scan here

- Studies on the effect of OCR on human reproduction and neonatal B-cell levels following maternal exposure have not been performed

- maternal exposure nave not been performed Transient peripheral B-cell depletion and Mymphocytopenia have been reported in some infants born to mothers exposed to other anti-CD20\* antibodies during pregnancy A previously reported overview<sup>4</sup> of pregnancy outcomes in OCR clinical trials across indications (RMS, PPMS, theumatoid arthritis and systemic lupus erythematosus; (dose range, 20–2,000 mg) concluded that women of childbearing potential should use contraception while receiving OCR and for the period of time recommended by local labeling after the last infusion<sup>12</sup> (rationale described in **Box 1**)

#### Box 1. Rationale for use of contraception during and after OCR treatment

- Effective contraception should be used while receiving OCR and for the period of time recommended by regional labelling<sup>4</sup> after the last infusion of OCR to provide for interpatient drug-elimination variability<sup>12</sup>
- Interpatient drug-elimination variability
- $\begin{array}{l} & \mbox{First-order elimination variants}, \\ & \mbox{First-order elimination processes are near-complete (>95%) after five half-lives \\ & \mbox{Average } t_{1/2} \mbox{ of OCR in patients with RMS is approximately } 26 \mbox{ days}^{12} \\ & \mbox{Near-complete elimination}^{\rm b} \mbox{ in patients with RMS with an average } t_{1/2} \mbox{ is approximately} \end{array}$ erage t., is approximately Near-complete elimination 19 weeks / 4.5 months
- Next-complete elimination<sup>5</sup> in a patient with the longest t<sub>1/2</sub> seen in female patients with RMS (53 days<sup>5</sup>) is approximately **38 weeks / 9 months** IgG1 antibodies, such as OCR, do **not** cross the placenta during the first trimester of pregnancy (3 months)<sup>6</sup> OCR transfer is assumed to compare to the
- DRR transfer is assumed to occur only after the 16<sup>th</sup> week of gestation, and therefore the foetus is protected from exposure during organogenesis<sup>6,7</sup>
- ns for the duration of effective contraception may vary for different health auth 95%) after 5 half-lives.

Preterm (n=6 [10%])

outcom (n=4 [7%

\_\_\_\_\_

This analysis includes OCR-exposed women with MS recorded from clinical trials and post-marketing experience of OCR

The database records information from all sources' and includes:
 Clinical trials: all pregnancy cases (including nonserious reports) and all cases with serious adverse events where OCR is considered 'suspect'

-Spontaneous reports: all cases (serious and nonserious) where OCR is considered 'suspect' -Pregnancy outcomes, including information about child health up to 1 year after birth, will be collected in ongoing OCR studies and the OCR pregnancy registry, and post-marketing experience will continue to be collected and assessed

Prospective and retrospective pregnancy reports were included in this analysis Maternal exposure was defined as receiving at least one OCR infusion at any time point before conception and/or during the pregnancy

An embryo/foetus was considered exposed to OCR *in utero* if the last infusion occurred within 3 months of conception or during pregnancy or if the date of infusion was unknown (see **Box 1**) what didnet like indicatement with emdet are and a real real real moments at the concentration and the second second

participated in these trials. This research was fundi led by Articulate Science. UK and funded by E Hof

#### OBJECTIVE

One ca

METHODS


Study Desig

To report pregnancy, foetal, neonatal and infant outcomes in female patients who became pregnant or who were breastfeeding during OCR trials and post-marketing analyses in multiple sclerosis (MS) up to 31 March 2019

#### Figure 2. Overview of outcomes in live births

One caesarean section (pre-eclampsia)
 One birth with

ths as the



#### CONCLUSIONS

- pregnancy / foetal outcomes
- The current update on pregnancy outcomes remains in line with previous reports
  B-cell levels in neonates following maternal exposure to ocrelizumab have not been studied in clinical trials
- Transient peripheral B-cell depletion and lymphocytopenia have been reported in some infants born to mothers exposed to other anti-CD20\* antibodies during pregnancy
- Although this report (to 31 March 2019) extends the knowledge base on preg the number of pregnancies remain small, limiting the ability to draw conclusion
- Pregnancy and child outcomes (1-year *post partum*) will continue to be collected, including: Ongoing ocrelizumab Phase II, III and IIIb studies and their respective open-label extension
- Pregnancy registry (WA40063)<sup>a</sup> and post-marketing experience (BA39732)<sup>a</sup>
   Women of childbearing potential should use contraception while receiving ocrelizumab and for the period of time defined in the local labelling documents after the last infusion

REFERENCES d by F. Hoffmann-La Roche Ltd, Basel, mann-La Roche Ltd, Basel, Switzerlan

Kane SV, Acquan LAC Attri 5 Gastrocomo Klink DT, et al. Clin Dev Immunol 2008;2 Wormser D et al. AAN 2018;Poster 367. Margulis AV et al. AAN 2018;Poster 372

#### DISCLOSURES

ACKNOWLEDGMENTS

ving on advisory boards from Biogen Idec, E Hoffmann-La Roche Ltd, Genzyme, Merck, Nov - I a Roche Ltd, D. Zecevic is an employee of E Hoffmann-La Roche Ltd. S. Vukusin has recei

## Figure 1. Overview of cumulative maternal exposure pregnancies

mber of women; <sup>b</sup>A further 10 pa

All Maternal Exposure Pregnancies in Patients With MS

36 (31)

31 (26 27 (23

4 (3) 17 (14)

28 (24)

in u

It futinus = I RA experienced two consecution -h of a healthy baby at term. RA, rheumatoid arthritis; SLE, systemic lupus er

- Clinical trials, N=78; post-marketing, N=189 (up to 31 March 2019)

In total, 57 of 62 recorded live births (92%) resulted in a healthy baby

(N=362)**			
Pregnancies in patients	Pregnancies in patients	Pregnancies in patients	Pregnancies in patients with unknown indication
with MS (N=267) <sup>3,5</sup>	with RA (N=22) <sup>a,c</sup>	with SLE (N=11) <sup>ad</sup>	(N=62)*
Mean maternal age, 33.2 years (age known, n=161)	Mean maternal age, 31.0 years (age known, n=22)	Mean maternal age, 28.0 years (age known, n=11)	Mean maternal age, 32.7 years (age known, n=8)

Outcomes of the 267 maternal exposure pregnancies in patients with MS are shown in Table 1

17 (36)

18 (38) 17 (36)

2 (4) 1 (2)

5 (11)

Seven pregnancies resulted in elective terminations (limited data available; six cases may be duplicate cases from Phase III studies)
 — Two pregnancies (both with foetal exposure) resulted in spontaneous abortions

Twenty-nine pregnancies had an unknown outcome or were lost to follow-up (foetal exposure in utero, n=6; no foetal exposure in utero, n=23)

An overview of outcomes of live births to mothers with MS, including births with abnormal outcomes are presented in Figure 2

Maternal Exposure Pregnancies in Patients With an Unknown Indication · There were 62 pregnancies in women for which the OCR indication was not reported as of

Eleven pregnancies were ongoing
 Thirteen pregnancies (12 with foetal exposure) resulted in live births

Infant Exposure Through Lactation (as of 31 March 2019) There were three cases of infants exposed to OCR via lactation:

Table 1. Outcomes of maternal exposure pregnancies in patients with MS 

ts received IFN β-1a or placebo d

uring pivotal trials and are exclude

(N= N=267) N (%)

86 (32)

62 (23) 57 (21)

3 (1)

80 (30)

=102)

n (%)

33 (32)

13 (13) 13 (13)

4 (4)

4 (4) 1 (1)

47 (46)

As of 31 March 2019, 362 pregnancies exposed to OCR have been reported (Figure 1)